Home

Antibody against Endoplasmic reticulum lipid raft associated 2 (Erlin-2; also known as anti-NET32 and anti-SPFH2)   Background:  Erlin-2 (endoplasmic reticulum lipid raft associated 2) a member of the SPFH domain-containing family of lipid raft-associated proteins. The protein is localized to lipid rafts of the endoplasmic reticulum and plays a critical role in inositol 1,4,5-trisphosphate (IP3) signaling by mediating ER-associated degradation of activated IP3 receptors. Mutations in the Erlin2 gene are a cause of spastic paraplegia-18 (SPG18). Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.  Technology Overview:  

• Polyclonal, affinity-purified
• Immunogen: amino acids 321-339 of rat Erlin-2

• Western blot 
• ELISA 
• Immunoprecipitation
• Immunofluorescence assays  

Antibody against Endoplasmic reticulum lipid raft associated 1 (Erlin-1; also known as anti-KE04 and anti-SPFH)   Background:  Erlin1 (endoplasmic reticulum lipid raft associated 1) is part of a protein complex that mediates degradation of inositol 1,4,5-trisphosphate receptors in the endoplasmic reticulum. The encoded protein also binds cholesterol and regulates the SREBP signaling pathway, which promotes cellular cholesterol homeostasis. Defects in this gene have been associated with spastic paraplegia 62. https://www.ncbi.nlm.nih.gov/gene/10613   Technology Overview:  

• Polyclonal, affinity-purified
• Immunogen: amino acids 332-346 of rat Erlin-1

• Western blot 
• ELISA 
• Immunoprecipitation
• Immunofluorescence assays  

Antibody against the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) type 2  Background: The inositol 1,4,5-trisphosphate receptor type 2 (IP3R2) is an intracellular Ca²-release channel located on the endoplasmic reticulum (ER). IP3R2 is characterized by a high sensitivity to both IP3 and ATP and is biphasically regulated by Ca². Furthermore, IP3R2 is modulated by various protein kinases. In addition to its regulation by protein kinase A, IP3R2 forms a complex with adenylate cyclase 6 and is directly regulated by cAMP. Finally, in the ER, IP3R2 is less mobile than the other IP3R isoforms, while its functional properties appear dominant in heterotetramers. TechnologyOverview Antibody against the inositol 1,4,5-trisphosphate (IP3) receptor (IP3R) type 2 Polyclonal, affinity-purified.  https://suny.technologypublisher.com/files/sites/2011-110.pngApplications:

• Western blot 
• ELISA \Immunoprecipitation
• Immunofluorescence assays 

Targeted gene silencing technology promotes corneal wound healing. Background: Ocular scarring after surgery, trauma, or infection leads to vision loss and blindness. Blindness due to corneal scarring can currently only be resolved by transplantation, necessitating new approaches in regenerative wound healing in the eye.Technology Overview:  A self-deliverable siRNA has been developed by Upstate Medical University researchers to specifically target a gene that modulates scarring in order to promote corneal wound healing. The approach has been validated ex vivo and in vivo, with treatment after corneal wounding resulting in faster wound closure, limited scarring, suppression of fibrotic markers, and restoration of corneal thickness. https://suny.technologypublisher.com/files/sites/110-2089.jpghttps://www.pexels.com/photo/human-eye-2609925/Advantages:  

• Targeted siRNA therapy circumvents the need for immunologically compatible corneal donors.
• In vivo studies demonstrate this therapy promotes 41.5% reduction in scarring

• Effective treatment for corneal scarring resulting from mechanical injuries, burns, infections or surgery.
• Model useful to study pathogenesis of fibrotic healing.